A new peer-reviewed study published in Acta Paediatrica finds that GLP-1 receptor agonist (GLP-1 RA) therapy meaningfully reshapes body composition in adolescents with obesity and may reduce key markers of metabolic syndrome — adding to a growing evidence base for these medications in younger patients.
What the Study Examined
Researchers conducted a real-world retrospective study of adolescents aged 12 to 18 with obesity who received multidisciplinary, lifestyle-based obesity care between 2020 and 2024. Within that group, some patients also received GLP-1 RA therapy — specifically liraglutide or semaglutide. The study's central aim was to track changes in body composition over time and examine how those changes connected to metabolic syndrome (MetS) components, which can include elevated blood pressure, blood sugar, and abnormal cholesterol levels.
The research stands out because it focuses specifically on adolescents, a population where long-term obesity and its downstream metabolic risks can set the stage for serious adult health complications.
Why This Matters for Patients and Families
For families navigating obesity care in teenagers, this study reinforces that GLP-1 medications are being actively researched — and used in real clinical settings — for patients well below typical adult age ranges. Both liraglutide and semaglutide are GLP-1 receptor agonists, the same drug class that includes widely recognized brands like Ozempic, Wegovy, and Victoza. The study's real-world design means the findings reflect how these drugs perform outside of tightly controlled clinical trials.
The association between body composition changes and metabolic syndrome components is also clinically significant. Reducing metabolic risk factors in adolescence could help prevent conditions like type 2 diabetes and cardiovascular disease from developing later in life.
Key takeaway: A real-world study of teens aged 12–18 found that GLP-1 receptor agonist therapy (liraglutide or semaglutide), used alongside multidisciplinary lifestyle care, was associated with changes in body composition and metabolic syndrome markers — suggesting potential benefits that extend beyond weight alone.
Important Limitations to Keep in Mind
Because this is a retrospective, real-world study rather than a randomized controlled trial, it cannot definitively prove that GLP-1 therapy caused the observed changes — only that associations exist. The abstract available does not specify exact percentages of body composition change, sample size, or the duration of follow-up, so the full published paper should be reviewed for those details. Families and clinicians should weigh these findings as part of a broader body of evidence, not as standalone proof of efficacy.
What to Watch Next
Regulatory approvals for GLP-1 medications in adolescents remain an evolving area. Researchers and clinicians will be watching for larger, prospective studies that can confirm these real-world findings with stronger evidence. As prescribing in younger age groups increases, more data on long-term safety, optimal dosing, and duration of treatment in teens will be critical for guiding clinical guidelines.
Frequently Asked Questions
If you have questions about GLP-1 medications for yourself or a family member — including whether they may be appropriate for an adolescent — speak with a licensed prescriber who can review the full clinical picture and provide personalized guidance.
- Peer-reviewed journal article, 'Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP-1 Receptor Agonist Therapy,' Acta Paediatrica, 2024/2025.